Review Article

Bolstering the Evidence Base for Integrating Abortion and HIV Care: A Literature Review

Ruth Manski, Amanda Dennis, Kelly Blanchard, Naomi Lince, and Dan Grossman

Ibis Reproductive Health, 17 Dunster Street, Suite 201, Cambridge, MA 02138, USA

Correspondence should be addressed to Ruth Manski, rmanski@ibisreproductivehealth.org

Received 14 June 2012; Accepted 6 November 2012

Copyright © 2012 Ruth Manski et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

HIV-positive women have abortions at similar rates to their HIV-negative counterparts, yet little is known about clinical outcomes of abortion for HIV-positive women or the best practices for abortion provision. To fill that gap, we conducted a literature review of clinical outcomes of surgical and medication abortion among HIV-positive women. We identified three studies on clinical outcomes of surgical abortion among HIV-positive women; none showed significant differences in infectious complications by HIV status. A review of seven articles on similar gynecological procedures found no differences in complications by HIV status. No studies evaluated medication abortion among HIV-positive women. However, we did find that previously expressed concerns regarding blood loss and vomiting related to medication abortion for HIV-positive women are unwarranted based on our review of data showing that significant blood loss and vomiting are rare and short lived among women. We conclude that although there is limited research that addresses clinical outcomes of abortion for HIV-positive women, existing data suggest that medication and surgical abortion are safe and appropriate. Sexual and reproductive health and HIV integration efforts must include both options to prevent maternal mortality and morbidity and to ensure that HIV-positive women and women at risk of HIV can make informed reproductive decisions.

1. Introduction

More than half of all people living with HIV worldwide are women, and most of them live in low- and middle-income countries [1]. Facilitating access to comprehensive sexual and reproductive health (SRH) services for women is currently the focus of many global health interventions, in part as a result of efforts to achieve Millennium Development Goal 5b (achieving universal access to SRH). However, few of these interventions focus on the specific challenges of facilitating access to SRH services for HIV-positive women. Fewer still focus on ensuring access to safe abortion for HIV-positive women.

HIV-positive women, like all women, require the right to access safe abortion services to prevent maternal mortality and morbidity and to be able to exercise their reproductive rights. Documented rates of unintended pregnancies among HIV-positive women highlight the importance of access to safe abortion for this population, for example, studies have shown that between 51% and 91% of pregnancies among HIV-positive women are unintended [2]. Furthermore, studies show that HIV-positive women have abortions at similar rates to their HIV-negative counterparts and seek abortions for many of the same reasons other women do, such as economic constraints or lack of partner support [3–9]. However, HIV-positive women face particular challenges when trying to access abortion services.

In addition to issues that affect women regardless of HIV-status, such as lack of information about abortion options, and financial barriers to abortion care, abortion is also legally restricted in many low- and middle-income countries where HIV is prevalent—limiting positive and negative women’s access to information and services. For example, in Southern Africa, where HIV rates are the highest in the world, abortion is only available without legal restriction in South Africa [10]. Furthermore, the confluence of stigma surrounding HIV/AIDS and abortion may make it even more difficult for HIV-positive women to access abortion services. Several studies have documented that HIV-positive women experience discrimination by health care providers based
on their reproductive decisions, with some women facing pressure to carry a child to term and others to have an abortion [11–13]. Furthermore, unique clinical questions, such as concerns about transmitting HIV during pregnancy and fears about how a pregnancy will affect a woman’s health, may impact HIV-positive women's abortion-related decision making [11]. Clinical concerns may also affect providers’ or policymakers’ decisions to make certain types of abortion services available to HIV-positive women. In particular, some authors have suggested that medication abortion may not be appropriate for HIV-positive women because they are at higher risk for anemia and that vomiting from medication abortion drugs may reduce the efficacy of HIV treatment drugs [12, 14].

The separation of abortion services from both SRH services and HIV services may present further obstacles to HIV-positive women's access to safe abortion care [15]. Efforts to integrate SRH and HIV services have become a priority in many health care settings, due to the potential benefits of integrating health care services, including increasing access to services and improving the quality of care [16]. However, integration research and programs have largely focused on including family planning and prevention and management of sexually transmitted diseases in HIV-focused services (or vice versa), but generally do not address safe abortion for HIV-positive or -negative women. Some models that could be used to integrate abortion and HIV services include providing abortion care in the same clinic where women receive HIV care and treatment or including referrals from one service to another. In settings where abortion is legally restricted, harm reduction counseling about safe and effective misoprostol regimens could be integrated into the HIV care setting.

Despite the documented need for abortion among HIV-positive women [3–8], there has been little research that addresses clinical outcomes of surgical and medication abortion for HIV-positive women or the best practices for abortion service provision and care. This paper reviews the existing data on clinical outcomes of surgical and medication abortion among HIV-positive women, with a focus on complication rates and adverse events. Given the limited amount of data available on this issue, we have selected a small group of gynecological procedures that are of similar or greater invasiveness when compared to abortion and review the literature for those procedures conducted among HIV-positive women. We, then, summarize data on blood loss and vomiting experienced by some women undergoing medication abortion to address concerns about the differential impact of these side effects on HIV-positive women.

2. Methods

We conducted two separate literature reviews which were supplemented with focused searches to identify additional literature. For the first review, from August to October 2011, we searched PubMed for studies that reported on clinical outcomes of surgical and medication abortion among HIV-positive women using the keywords “abortion” or “termination of pregnancy” and “HIV.” Only original research studies published in English with female human subjects were eligible for inclusion. We scanned the titles, abstracts, and citations of all articles and removed any that were irrelevant, such as articles focusing on the reproductive rights of HIV-positive women or the characteristics of HIV-positive women seeking abortion care.

For the second review, focusing on gynecological procedures deemed to be similar to abortion as explained previously, from March to May 2012, we searched PubMed using the following search terms: “HIV” and “LEEP” (loop electrosurgical excision procedure), “laparoscopy,” “cone biopsy,” “fibroid treatment,” “endometrial biopsy,” “endometriosis management,” “myomectomy,” or “uterine cervical neoplasms diagnosis, surgery, or therapy [MESH].” (Medical Subject Headings (MeSH) is the National Library of Medicine controlled vocabulary thesaurus used for indexing articles for PubMed). We did not find any studies using the search terms “HIV” and “fibroid treatment,” “endometriosis management,” or “myomectomy.” As in our first review, we considered original research studies published in English with female human subjects eligible for inclusion. We scanned the titles, abstracts, and citations of all articles and removed any that did not discuss complications among HIV-positive women.

For the third and fourth searches, to address concerns expressed regarding medication abortion for HIV-positive women, in October 2011, we searched PubMed for articles on (1) changes in hemoglobin levels due to blood loss from medication abortion where anemia is prevalent (discussed below) and (2) the frequency and duration of vomiting due to medication abortion drugs. Our aim was not to conduct an exhaustive review of this expansive body of the literature, but rather to identify key articles and identify the severity and frequency of blood loss and vomiting among women choosing medication abortion.

To identify articles on blood loss, we limited the search to India, because there is a high prevalence of anemia among Indian pregnant women [17, 18], and a large number of medication abortion studies have been conducted in India. Our search terms included “medical abortion” or “medication abortion” and “India;” these results were then narrowed down by searching within the text of each article for the keywords “anemia” or “hemoglobin.” Only original research studies published in English with female human subjects were considered eligible for inclusion. We scanned the titles, abstracts, and citations of all articles and removed any that did not include “anemia” or “hemoglobin” as a keyword.

To identify articles on vomiting associated with medication abortion drugs, we used the search terms “medical abortion” or “medication abortion” and “side effects.” The search results were then narrowed down by searching within the text of each article for the keyword “vomit.” Only English studies with female human subjects were eligible for inclusion. We reviewed both original research articles and literature reviews. We scanned the titles, abstracts, and citations of all articles and removed any that did not include information on the frequency and/or duration of vomiting. We ultimately focused on the findings from a literature review that summarized data on vomiting from medication...
abortion drugs. None of the searches were limited to specific dates of publication.

3. Results

Our first literature review on clinical outcomes of surgical and medication abortion identified 559 articles. No articles discussed clinical outcomes of medication abortion among HIV-positive women. Three articles that discussed clinical outcomes of surgical abortion among HIV-positive women met our criteria and were included in our review.

3.1. Surgical Abortion. Detailed information on each of the three articles that examined clinical outcomes of surgical abortion among HIV-positive women is included in Table 1. The first study, conducted in urban Uganda, explored whether HIV was a risk factor for postabortion endometritis-myometritis (PAEM) [19]. PAEM was defined as an incomplete abortion (admitted induced or spontaneous abortion) with intrauterine infection. Of women with PAEM, 32.7% were HIV-positive, and of women without PAEM, 36.5% were HIV-positive. The difference was not statistically significant.

The second study examined morbidity associated with curettage for abortion among HIV-positive and -negative women in a public hospital in Texas, USA [20]. Women with septic abortions were excluded from the study, and only a minority of subjects had AIDS. There were higher numbers of anesthesia-related complications and instances of retained placenta among HIV-positive women. However, the numbers were small (two and three, resp.), and the authors posit that instances of retained placenta were unlikely related to HIV-status as there is no known biologic susceptibility to retained placental tissue among HIV-positive women. Three percent of HIV-positive women and 1% of HIV-negative women experienced infectious complications; the difference between groups was not significant.

In the third study, the authors compared the risks of postoperative morbidity among HIV-positive and -negative women undergoing six categories of surgical procedures, including curettage [21]. Among patients experiencing major and minor complications after curettage (e.g., fever requiring antibiotics, additional surgical procedures, anemia, urinary tract infection, development of endometriosis and lochlosterasis after obstetric procedures, and disseminated intravascular coagulation), 9.7% were HIV-positive and 1.4% were HIV-negative. However, the point estimates must be viewed with caution due to the small number of women in the sample who experienced relevant complications (7 HIV-positive women and 1 HIV-negative woman), the width of the confidence intervals (0.92–63.84), and the lack of statistical significance; it was also impossible to separate out minor from major complications based on the published data.

3.2. Other Gynecological Procedures. Due to the lack of data specifically addressing clinical outcomes of surgical abortion among HIV-positive women, we reviewed the literature on clinical outcomes of gynecological procedures deemed to be of similar or more invasiveness to abortion. We identified 144 articles. Seven articles, which provide clinical outcomes after LEEP and laparoscopic sterilization among HIV-positive women, met our inclusion criteria.

We summarize details of each of the seven studies in Table 2. We found one article on laparoscopic sterilization for HIV-positive women in Thailand [22]. The authors found that laparoscopic sterilization was safe. No study participants experienced immediate or subsequent surgical complications, though the authors did not provide detail regarding what complications were measured. Six studies examined complications among HIV-positive women undergoing LEEP. One study, conducted in Kenya, measured women’s self reports of the presence and severity of complications, including bleeding, discharge, and pain [23]. No participants reported severe symptoms, and only 1% (n = 1) reported moderate symptoms. The other five studies, conducted in Thailand and Zambia, measured postoperative and intraoperative bleeding-related complications including hemorrhage and rates of postoperative infection among HIV-positive and -negative women undergoing LEEP [24–28]. There were no significant differences in complication rates based on HIV-status.

3.3. Medication Abortion. To address concerns raised in the literature regarding risks of blood loss and vomiting related to medication abortion for HIV-positive women, we conducted a review of the existing data on blood loss with medication abortion in India—a setting with a high prevalence of anemia. Our literature search identified 39 articles, five of which were included in our review. These are summarized in Table 3. While no studies were identified that specifically measured outcomes of medication abortion among women with anemia, all of the studies were conducted in India where the majority of pregnant women have anemia [17, 18]. Three of these articles reported findings from multicountry studies conducted in India, Cuba, and China [29–31]; findings reported in the text and Table 3 focus only on the India data.

 Clinically significant changes in hemoglobin levels due to blood loss from medication abortion were rare in all studies. Mean changes in hemoglobin levels between study enrollment and the follow-up visit (12–14 days later) ranged from 0.1 to 0.29 gm/dL, and the percent of women whose hemoglobin levels dropped 2 gm/dL ranged from 1.2 to 4% [29–33]. In one study, one woman required a blood transfusion [30].

Our review of vomiting from medication abortion identified 147 articles, of which 66 were relevant. One literature review of nine studies comparing medication abortion practiced in homes and clinics using the evidence-based medication abortion regimen of 200 mg mifepristone and 400 µg misoprostol orally provided vomiting data for four studies conducted in Albania, Nepal, Turkey, and Vietnam [34]. Reported rates of vomiting ranged from 11.5 to 33.7%, and vomiting lasted an average of less than one day. Other relevant articles identified in our search reported similar rates and durations of vomiting among women undergoing...
| Authors               | Study type | Setting                                      | Population                                      | Number | Findings                                                                                                                                 |
|----------------------|------------|----------------------------------------------|-------------------------------------------------|--------|------------------------------------------------------------------------------------------------------------------------------------------|
| Grubert et al. (2002) [21] | Retrospective | Germany, specialized outpatient clinic       | HIV-positive and -negative women undergoing curettage | 72     | 9.7% ($n = 7$) of HIV-positive women and 1.4% ($n = 1$) of HIV-negative women experienced complications; difference was not statistically significant ($P = 0.063$; OR, 7.65; 95% CI, 0.92–63.84) |
| Okong et al. (2002) [19]  | Prospective | Uganda, gynecological ward at urban hospital | HIV-positive and -negative women with and without postabortion endometritis-myometritis (PAEM) | 158    | 32.7% ($n = 17$) of women with PAEM were HIV-positive, and 36.5% ($n = 38$) of women without PAEM were HIV-positive; difference was not statistically significant (OR, 0.84; 95% CI 0.39–1.80) |
| Stuart et al. (2004) [20] | Retrospective | Texas, USA, public hospital                   | HIV-positive and -negative women undergoing curettage for abortion | 284    | 3% ($n = 2$) of HIV-positive women and 1% ($n = 3$) of HIV-negative women experienced infectious complications; difference was not statistically significant ($P = 0.435$). 3% ($n = 2$) of HIV-positive women and no HIV-negative women experienced anesthetic complications; 4% ($n = 3$) of HIV-positive women and 0% ($n = 1$) of HIV-negative women experienced retained placenta. |
| Authors             | Study type | Setting                              | Population                                                                 | Number | Findings                                                                 |
|--------------------|------------|--------------------------------------|---------------------------------------------------------------------------|--------|--------------------------------------------------------------------------|
| Intaraprasert et al. (1996) [22] | Retrospective | Thailand, university hospital | HIV-positive women undergoing laparoscopic sterilization                     | 18     | No immediate or subsequent surgical complications                        |
| Kietpeerakool et al. (2009) [26] | Prospective | Thailand, university hospital | HIV-positive and -negative women undergoing LEEP Women with abnormal cervical cytology undergoing LEEP | 789    | HIV infection was not significantly associated with LEEP complications (OR, 0.41; 95% CI, 0.15–1.15) |
| Kietpeerakool et al. (2006) [25] | Prospective | Thailand, university hospital | HIV-positive and -negative women undergoing LEEP for CIN                   | 206    | HIV was not an independent risk factor for LEEP complications (P = 0.49) |
| Kietpeerakool et al. (2006) [24] | Retrospective | Thailand, university hospital | HIV-positive and -negative women undergoing LEEP for CIN                   | 120    | HIV was not significantly associated with LEEP complications (P = 0.24)   |
| Pfaendler et al. (2008) [27] | Prospective | Zambia, primary care clinics and tertiary hospital | Women in a screen and treat cervical cancer prevention program undergoing LEEP | 748    | Number of women experiencing complications was not large enough to compare significant differences in complications based on HIV-status; complication rates were low in both groups |
| Sutthichon and Kietpeerakool (2009) [28] | Retrospective | Thailand, university hospital | Women undergoing their first LEEP                                           | 857    | HIV status was not a significant predictor of perioperative complications |
| Woo et al. (2011) [23] | Prospective | Kenya, dinics | HIV-positive women who returned for a 4-week followup after LEEP           | 180    | No participants reported severe symptoms; 1% (n = 1) reported moderate symptoms; 99% (n = 179) reported very mild to mild symptoms |
Table 3: Studies summarizing data on blood loss due to medication abortion in India.

| Authors            | Study type | Setting                       | Population                                                                 | Number | Medication abortion regimen                              | Findings                                                                 |
|--------------------|------------|-------------------------------|---------------------------------------------------------------------------|--------|-----------------------------------------------------------|--------------------------------------------------------------------------|
| Coyaji et al. (2002) [33] | Prospective | India, urban and rural hospitals | Pregnant women with gestations of ≤63 days in the urban sites and ≤56 days in the rural site | 900    | 600 mg mifepristone and 400 µg misoprostol; oral         | Mean change in hemoglobin levels 0.1–0.2 gm/dL                           |
| Elul et al. (1999) [31] | Retrospective | India, urban hospital         | Pregnant women with amenorrhea ≤56 days                                   | 250    | 600 mg mifepristone and 400 µg misoprostol; oral         | Mean change in hemoglobin levels −0.29 gm/dL                             |
| Harper et al. (1998) [29] | Prospective | India, urban hospital         | Pregnant women with amenorrhea ≤56 days                                   | 250    | 600 mg mifepristone and 400 µg misoprostol; oral         | 4% of women experienced drop in hemoglobin levels >2 gm/dL               |
| Mundle et al. (2007) [32] | Prospective | India, primary health care center | Pregnant women with amenorrhea ≤56 days                                   | 149    | 200 mg mifepristone and 400 µg misoprostol; sublingual   | Median change in hemoglobin levels 0.1 gm/dL; no serious complications   |
| Winikoff et al. (1997) [30] | Prospective | India, urban hospital         | Pregnant women with amenorrhea ≤56 days                                   | 250    | 600 mg mifepristone and 400 µg misoprostol; oral         | Mean change in hemoglobin levels −0.29 gm/dL; 1.2% of women experienced drop >2 gm/dL |
medication abortion, although there is variation based on the medication abortion drug regimen and other study variables.

4. Discussion

Our review identified no studies that assessed clinical outcomes of medication abortion and three studies that assessed clinical outcomes of surgical abortion among HIV-positive women. Despite the few studies, existing data show that adverse outcomes of surgical abortion in HIV-positive women are low and occur at similar rates to HIV-negative women. Similarly, the literature on LEEP and laparoscopic sterilization, two procedures that are of similar or more invasiveness to abortion, shows that adverse events when these procedures are performed among HIV-positive women are uncommon and not significantly different according to HIV-status. In addition to this data, clinical guidelines on the management of cervical intraepithelial neoplasia (CIN) specify that recommended treatment for HIV-positive women is the same as for women in the general population [35]. In the absence of other data, these findings can be used to make inferences about the safety of surgical abortion for HIV-positive women.

Data also suggests that medication abortion is safe for HIV-positive women. First, data reviewed on blood loss from medication abortion in India, where there is a high prevalence of anemia among pregnant women [17, 18], shows that significant changes in hemoglobin levels are infrequent. Additionally, because the majority of women do not experience vomiting associated with use of medication abortion drugs, and, for those that do, the average duration is less than one day, the impact of vomiting on HIV treatment drugs is likely short lived. It is also important to note that vomiting is common during pregnancy and would likely last much longer than one day. To avoid any potential (although unlikely) reductions in HIV treatment drug efficacy, women could repeat a dose if vomiting occurs less than one hour after taking HIV treatment drugs and/or begin the medication abortion drug regimen at least one hour after HIV treatment drugs [36]. Further documentation of the safety of medication abortion for HIV-positive women comes from medication abortion studies in HIV-prevalent countries. While there is a need for more research, clinical outcomes of medication abortion from countries with a high prevalence of HIV, like South Africa, are similar to reports from countries with a lower HIV prevalence [37].

There are several limitations of this literature review. First, the outcome of interest was not consistently defined across surgical abortion studies, making it difficult to compare findings. In addition, the varying legal contexts and surgical methods of abortion, as well as inclusion or exclusion of women with septic abortions, limit the ability to make generalizations about clinical outcomes of abortion for HIV-positive women. In the absence of specific data on surgical and medication abortion among HIV-positive women, our review on clinical outcomes of LEEP and laparoscopic sterilization as well as blood loss and vomiting from medication abortion may provide helpful insight regarding abortion care for HIV-positive women. However, we acknowledge that there are clinical differences when considering abortion and LEEP or laparoscopic sterilization, and the data presented here on blood loss and vomiting from medication abortion are not focused on HIV-positive women.

Further research is needed which evaluates the complications of safe abortion among HIV-positive and -negative women. Research documenting clinical experience and acceptability of medication and surgical abortion among HIV-positive women would be useful to inform discussions about standards of care. Furthermore, research examining HIV-positive women’s choice of method and the impact of particular methods on HIV-treatment would strengthen recommendations and identify best practices for abortion care for HIV-positive women. Until such data are available, we are confident that our review provides a strong argument for offering HIV-positive women both surgical and medication abortion where available; offering women the choice of methods would be ideal.

Efforts aimed at integrating abortion services into SRH and HIV services are critical to protecting and promoting the reproductive health and rights of HIV-positive women. SRH and HIV providers not only need to have the clinical skills and equipment to perform abortions, but also the capacity to provide nonjudgmental counseling to HIV-positive women on their reproductive rights and choices to meet women’s sexual and reproductive health needs. In addition, expanding access to and providing HIV-positive women who do not wish to become pregnant with the full range of contraceptive options is a critical component of SRH/HIV integration and could support women in achieving their reproductive goals.

We recognize that there are policy- and service-level challenges to integrating SRH and HIV services, such as legal and funding constraints, lack of national guidelines on integration, and staffing shortages [38, 39]. In settings where abortion is legally restricted, women could be provided with harm reduction counseling about safe and effective misoprostol regimens, which has been shown to decrease complications from unsafe abortion [40], or, in other cases, women with HIV might be eligible for legal abortion if continuing the pregnancy would jeopardize their health. Further, advocates for women’s health must hold accountable programs and policies that do not address women’s comprehensive SRH needs, including HIV and safe abortion care. The International HIV/AIDS Alliance names abortion as a key HIV and SRH intervention and outlines strategies for how to integrate safe abortion and postabortion care into HIV services [41]. Advocates for HIV-positive women should build on these recommendations and the momentum generated by the 2011 report from the United Nations Special Rapporteur on the Right to Health that calls for the removal of legal barriers to access to abortion for all women to improve women’s health worldwide [42].

5. Conclusion

Based on the existing data on clinical outcomes of abortion and other gynecological procedures for HIV-positive women,
surgical and medication abortion appear to be both safe and appropriate options for HIV-positive women. Improving access to safe abortion services has been shown to lead to significant reductions in maternal mortality and morbidity. Efforts to integrate SRH and HIV services should be expanded to incorporate information about safe abortion and referrals, and/or provision of safe abortion services, and consider the specific needs of HIV-positive women.

Conflict of Interests

The authors declare no conflict of interests or financial interests in any product or service mentioned in this paper, including grants, employment, gifts, stock, holdings, or honoraria.

Acknowledgments

The authors would like to thank Annie Kiel for help with the literature review and Kelsey Holt, Kate Grindlay, Lwazi Mdlopane, and Britt Wahlin for their advice and feedback.

References

[1] The Henry J. Kaiser Family Foundation, The Global HIV/AIDS Epidemic, The Henry J. Kaiser Family Foundation, Menlo Park, Calif, USA, 2011, http://www.kff.org/hivaids/3030.cfm.
[2] The President's Emergency Plan for AIDS Relief (PEPFAR), FY 2012 Country Operational Plan (COP) Guidance, PEPFAR, Washington, DC, USA, 2011, http://www.pepfar.gov/documents/organization/169694.pdf.
[3] D. D. Abeni, D. Porta, and C. A. Perucci, "Deliveries, abortion and HIV-1 infection in Rome, 1989–1994,” European Journal of Epidemiology, vol. 13, no. 4, pp. 373–378, 1997.
[4] B. H. B. van Benthem, I. de Vincenzi, M. C. Delmas, C. Larsen, A. van den Hoek, and M. Prins, "Pregnancies before and after HIV diagnosis in a European cohort of HIV-infected women," Journal of Acquired Immune Deficiency Syndromes, vol. 14, no. 14, pp. 2171–2178, 2000.
[5] B. K. Chi, T. Gammeltoft, N. T. T. Nam, and V. Rasch, "Induced abortion among HIV-positive women in Quang Ninh and Hai Phong, Vietnam,” Tropical Medicine and International Health, vol. 15, no. 10, pp. 1172–1178, 2010.
[6] L. S. Massad, G. Springer, L. Jacobson et al., "Pregnancy rates and predictors of conception, miscarriage and abortion in US women with HIV,” Journal of Acquired Immune Deficiency Syndromes, vol. 18, no. 2, pp. 281–286, 2004.
[7] A. Bongain, A. Berrebi, E. Mariné-Barjoan et al., "Changing trends in pregnancy outcome among HIV-infected women between 1985 and 1997 in two southern French university hospitals," European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 104, no. 2, pp. 124–128, 2002.
[8] R. S. Remis, E. L. Eason, R. W. H. Palmer et al., "HIV infection among women undergoing abortion in Montreal," Canadian Medical Association Journal, vol. 153, no. 9, pp. 1271–1279, 1995.
[9] Ipas, HIV/AIDS, Unwanted pregnancy, and Abortion: The Situation Today and What Needs to be Done, Ipas, Chapel Hill, NC, USA, 2008, http://www.ipas.org/~media/Files/Ipas%20Publications/HIVPREABOE08 ashx.
[10] Center for Reproductive Rights, The World’s Abortion Laws 2012, Center for Reproductive Rights, New York, NY, USA, 2012, http://worldabortionlaws.com/map/.
[11] B. K. Chi, N. T. T. Hanh, V. Rasch, and T. Gammeltoft, "Induced abortion among HIV-positive women in Northern Vietnam: exploring reproductive dilemmas," Culture, Health and Sexuality, vol. 12, supplement 1, pp. S41–S54, 2010.
[12] Ipas, HIV/AIDS and Reproductive Health: Sensitive and Neglected Issues, Ipas, Chapel Hill, NC, USA, 2005, http://www.ipas.org/~media/Files/Ipas%20Publications/ HVLITREV05en.ashx.
[13] J. Harries, D. Cooper, L. Myer, H. Bracken, V. Zweigenthal, and P. Orner, “Policy maker and health care provider perspectives on reproductive decision-making amongst HIV-infected individuals in South Africa,” BMC Public Health, vol. 7, article 282, 2007.
[14] M. de Bruyn, “Safe abortion for HIV-positive women with unwanted pregnancy: a reproductive right,” Reproductive Health Matters, vol. 11, no. 22, pp. 152–161, 2003.
[15] P. Orner, M. de Bruyn, and D. Cooper, “It hurts, but I don’t have a choice, I’m not working and I’m sick: Decisions and experiences regarding abortion of women living with HIV in Cape Town, South Africa,” Culture, Health and Sexuality, vol. 13, no. 7, pp. 781–795, 2011.
[16] International Planned Parenthood Federation (IPPF), University of California San Francisco (UCSF), UNAIDS, United Nations Population Fund (UNFPA), and World Health Organization (WHO), Linkages: Evidence Review and Recommendations, IPPF, UCSF, UNAIDS, UNFPA, WHO, London, UK, 2009, http://data.unaids.org/pub/Agenda2009/ 2009_linkages_evidence_review_en.pdf.
[17] WHO, Worldwide Prevalence of Anaemia 1993–2005: WHO Global Database on Anaemia, WHO, Geneva, Switzerland, 2008, http://apps.who.int/iris/bitstream/10665/43894/1/ 9789241596657_eng.pdf.
[18] K. Kalaivani, “Prevalence and consequences of anaemia in pregnancy,” Indian Journal of Medical Research, vol. 130, no. 5, pp. 627–633, 2009.
[19] P. Okong, B. Biryahwaho, and S. Bergström, “Post-abortion endometritis-myometritis and HIV infection,” International Journal of STD and AIDS, vol. 13, no. 11, pp. 729–732, 2002.
[20] S. J. Stuart, J. S. Sheffield, J. B. Hill, D. D. McIntire, B. McElwee, and G. D. Wendel, “Morbidity that is associated with curettage for the management of spontaneous and induced abortion in women who are infected with HIV,” American Journal of Obstetrics and Gynecology, vol. 191, no. 3, pp. 993– 997, 2004.
[21] T. A. Grubert, D. Reindell, R. Kastner et al., “Rates of post-operative complications among human immunodeficiency virus-infected women who have undergone obstetric and gynecologic surgical procedures,” HIV/AIDS, vol. 34, no. 6, pp. 822–830, 2002.
[22] S. Intaraprрасert, S. Taneepanichskul, and K. Chaturachinda, “Laparoscopic sterilization in HIV-1-positive women,” Contraception, vol. 54, no. 5, pp. 305–307, 1996.
[23] V. G. Woo, C. R. Cohen, E. A. Bukusi, and M. J. Hutchko, “Loop electrosurgical excision procedure: safety and tolerability among human immunodeficiency virus-positive Kenyan women,” Obstetrics and Gynecology, vol. 118, no. 3, pp. 554– 559, 2011.
[24] C. Kietpeerakool, I. Srisomboon, P. Suprasert et al., “Outcomes of loop electrosurgical excision procedure for cervical neoplasia in human immunodeficiency virus-infected

AIDS Research and Treatment
women,” *International Journal of Gynecological Cancer*, vol. 16, no. 3, pp. 1082–1088, 2006.

[25] C. Kietpeerakool, J. Srisomboon, A. Khobjai, A. Chandacham, and U. Tuksinsook, “Complications of loop electrosurgical excision procedure for cervical neoplasia: a prospective study,” *Journal of the Medical Association of Thailand*, vol. 89, no. 5, pp. 583–587, 2006.

[26] C. Kietpeerakool, P. Suprasert, and J. Srisomboon, “Outcome of loop electrosurgical excision for HIV-positive women in a low-resource outpatient setting,” *International Journal of Gynecology and Obstetrics*, vol. 105, no. 1, pp. 10–13, 2009.

[27] K. S. Pfaendler, M. H. Mwanahamuntu, V. V. Sahasrabuddhe, V. Mudenda, J. S. A. Stringer, and G. P. Parham, “Management of cryotherapy-ineligible women in a “screen-and-treat” cervical cancer prevention program targeting HIV-infected women in Zambia: lessons from the field,” *Gynecologic Oncology*, vol. 110, no. 3, pp. 402–407, 2008.

[28] P. Sutthichon and C. Kietpeerakool, “Perioperative complications of an outpatient loop electrosurgical excision procedure: a review of 857 consecutive cases,” *Asian Pacific Journal of Cancer Prevention*, vol. 10, no. 3, pp. 351–354, 2009.

[29] C. Harper, B. Winikoff, C. Ellertson, and K. Coyaji, “Blood loss with mifepristone-misoprostol abortion: measures from a trial in China, Cuba and India,” *International Journal of Gynecology and Obstetrics*, vol. 63, no. 1, pp. 39–49, 1998.

[30] B. Winikoff, I. Sivin, K. J. Coyaji et al., “Safety, efficacy, and acceptability of medical abortion in China, Cuba, and India: a comparative trial of mifepristone-misoprostol versus surgical abortion,” *American Journal of Obstetrics and Gynecology*, vol. 176, no. 2, pp. 431–437, 1997.

[31] B. Elul, C. Ellertson, B. Winikoff, and K. Coyaji, “Side effects of mifepristone-misoprostol abortion versus surgical abortion: data from a trial in China, Cuba, and India,” *Contraception*, vol. 59, no. 2, pp. 107–114, 1999.

[32] S. Mundle, B. Elul, A. Anand, S. Kalyanwala, and S. Ughade, "Increasing access to safe abortion services in rural India: experiences with medical abortion in a primary health center,” *Contraception*, vol. 76, no. 1, pp. 66–70, 2007.

[33] K. Coyaji, B. Elul, U. Krishna et al., “Mifepristone-misoprostol abortion: a trial in rural and urban Maharashtra, India,” *Contraception*, vol. 66, no. 1, pp. 33–40, 2002.

[34] T. D. Ngo, M. H. Park, H. Shakura, and C. Free, “Comparative effectiveness, safety and acceptability of medical abortion at home and in a clinic: a systematic review,” *Bulletin of the World Health Organization*, vol. 89, no. 5, pp. 360–370, 2011.

[35] A. Fakoya, H. Lamba, N. Mackie et al., "British HIV Association, BASHH and FSRH guidelines for the management of the sexual and reproductive health of people living with HIV infection 2008,” *HIV Medicine*, vol. 9, no. 9, pp. 681–720, 2008.

[36] NAM, *Nausea and Vomiting*. NAM Publications, London, UK, 2012, http://www.aidsmap.com/Nausea-and-vomiting/page/1730427/.

[37] M. Kawonga, K. Blanchard, D. Cooper et al., "Integrating medical abortion into safe abortion services: experience from three pilot sites in South Africa,” *Journal of Family Planning and Reproductive Health Care*, vol. 34, no. 3, pp. 159–164, 2008.

[38] J. A. Smit, K. Church, C. Milford, A. D. Harrison, and M. E. Bekinska, “Key informant perspectives on policy- and service-level challenges and opportunities for delivering integrated sexual and reproductive health and HIV care in South Africa,” *BMC Health Services Research*, vol. 12, article 48, 2012.

[39] R. Wilcher and W. Cates, “Reproductive choices for women with HIV,” *Bulletin of the World Health Organization*, vol. 87, no. 11, pp. 833–839, 2009.

[40] L. Briozzo, G. Vidiella, F. Rodriguez, M. Gorgoroso, A. Fau ndes, and J. E. Pons, “A risk reduction strategy to prevent maternal deaths associated with unsafe abortion,” *International Journal of Gynecology and Obstetrics*, vol. 95, no. 2, pp. 221–226, 2006.

[41] International HIV/AIDS Alliance, *Good Practice Guide: Integration of HIV and Sexual and Reproductive Health and Rights*, International HIV/AIDS Alliance, Hove, UK, 2010, http://www.aidsalliance.org/includes/Publication/SRH_GPG_BW_060611.pdf.

[42] United Nations, General Assembly, *Interim Report of the Special Rapporteur on the Right of Everyone to the Enjoyment of the Highest Attainable Standard of Physical and Mental Health*, United Nations, General Assembly, Geneva, Switzerland, 2011, http://www.un.org/ga/search/view_doc.asp?symbol=A/66/254.